Olivier Brandicourt (AP Images)

Ex-Sanofi chief Olivi­er Brandi­court, cur­rent Black­stone ad­vi­sor, jumps on Al­ny­lam board

For­mer Sanofi chief Olivi­er Brandi­court, who de­part­ed his post with an un­ex­pect­ed ear­ly re­tire­ment last year, has made his move — as most C-suite ex­ec­u­tives in­evitably do — to be­come a di­rec­tor on the board of a bio­phar­ma com­pa­ny.

RNAi play­er Al­ny­lam is Brandi­court’s des­ti­na­tion. Mean­while, the Cam­bridge, Mass­a­chu­setts-based drug­mak­er — which pi­o­neered the first ap­proval in the field — al­so dis­closed the re­tire­ment of Al­ny­lam co-founder Dr. Paul Schim­mel from its board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.